Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03612713 · ClinicalTrials.gov registry record · Early Phase 1
Influence of Medication on Functional Connectivity
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT03612713 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 20 participants.
The verdict
NCT03612713, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study will assess the effects of acute low-dose opioid administration on functional neuroimaging measures in healthy individuals
Interventions
- DRUG Placebo First
- DRUG Oxycodone Medication First
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-10-30 |
| Est. Completion | 2022-06-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03612713
The ClinicalTrials.gov registry entry for NCT03612713 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo First is the first listed.
NCT03612713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03612713 about?
NCT03612713 is a clinical study titled "Influence of Medication on Functional Connectivity". This study will assess the effects of acute low-dose opioid administration on functional neuroimaging measures in healthy individuals
What is the current status of trial NCT03612713?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2018-10-30. Estimated completion is 2022-06-02.
What interventions are being tested in trial NCT03612713?
The interventions under investigation include: Placebo First (DRUG), Oxycodone Medication First (DRUG).
Who is sponsoring clinical trial NCT03612713?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.